logo
AI vs Physicians in 2050: Happy Future or No Future?

AI vs Physicians in 2050: Happy Future or No Future?

Medscape21-05-2025

Last February, Microsoft co-founder and billionaire philanthropist Bill Gates appeared on The Tonight Show and shared some bold predictions about artificial intelligence (AI). In just a decade, he told host Jimmy Fallon, AI will be capable of 'great medical advice' and humans will no longer be needed 'for most things.'
It's not the first time we've heard claims that AI will soon replace doctors, and it's usually hard to take seriously. But then just last month, on the heels of Gates's tech forecast, researchers at Google published a study introducing Articulate Medical Intelligence Explorer (AMIE), an AI system designed for clinical interactions and diagnostic dialogue.
Mike Schaekermann, MD
The trial 'involved specialist physicians and patient actors [and] assessed diagnostic accuracy, communication, empathy, and management reasoning,' says Mike Schaekermann, PhD, a research scientist at Google Health involved in the study. 'AMIE often performed comparably or better than primary care physicians in these specific research settings.' Given the provided prompts, AI achieved a correct diagnosis 60% of time compared with about 34% for unassisted human doctors.
It doesn't mean doctors are in danger of being replaced by AI anytime soon — now, today, in 2025 — but it does beg the question: How about in 25 years? Tech years can be like dog years. Google is already partnering with Beth Israel Deaconess Medical Center on a prospective research study, 'to explore how AMIE might help gather information previsit and understand clinician and patient perceptions in a real-world setting,' says Schaekermann.
As the technology continues to advance at a sprint, and researchers continue to explore AI's applications not just as a tool but how they perform in head-to-head competitions with human physicians, is it possible that by 2050 doctors will be replaced or their roles reduced by new tech?
An AI Upheaval May (or May Not) Be Coming
Let's play the science fiction card. Replacing doctors with machines feels like science fiction because it feels imaginary. Today. But everything from the internet to Wi-Fi to touch-screen supercomputers in our pockets felt imaginary at one time.
Science fiction-turned-facts incoming: Beckman Institute researchers recently developed an AI model that can accurately identify tumors and diseases in medical images. London's Institute of Cancer Research has created a prototype test that uses AI to predict the best drug combinations for cancer patients in less than 48 hours. King's College Hospital, also in London, is recruiting patients for a clinical trial of a new AI tool that can identify abnormalities on MRI head scans, and both Med-PaLM and ChatGPT have passed the US medical licensing exam.
Luciana D'Adderio, PhD
AI is already driving significant changes in stroke diagnosis, says Luciana D'Adderio, PhD, Turing Fellow with the Alan Turing Institute and founder of the behavioural AI lab at Edinburgh University's Centre for Medical Informatics. Her research, published last January, found that rather than using AI to confirm their diagnosis, clinicians could now use AI to make an initial assessment. 'Potentially, these changes can benefit patients, improving the detection rate of large vessel occlusions,' says D'Adderio, 'but perhaps more importantly by providing the clinician with immediate predictive maps of the extent of brain damage and the potential for treatment.'
And it's only beginning. 'By 2050, I expect AI to be a deeply integrated, horizontal layer across the entire diagnostic pathology workflow,' says Faisal Mahmood, PhD, associate professor of pathology at Brigham and Women's Hospital and Harvard Medical School, whose lab is devoted to machine learning and data fusion. 'Routine slides will be automatically triaged, allowing pathologists to focus on complex cases. AI will preorder ancillary tests based on predictive models, and agentic, generative AI systems will serve as intelligent assistants — answering diagnostic questions, highlighting key findings, and even drafting structured pathology reports.'
That feels like the feel-good scenario: a truly fast, accurate, dependable technology that augments the physician/patient interaction and improves care. Neither physicians nor patients would argue against such a future.
David Dranove, PhD
David Dranove, PhD, paints a less rosy picture. The Walter J. McNerney Professor of Health Industry Management at Northwestern University's Kellogg School of Management has studied how AI could change the future of healthcare and suggests that by 2050, AI could 'more than adequately substitute for the radiologist, and presumably at a much lower cost because AI can be scaled.'
Humans will still be needed in medicine, if only because humans are 'vastly more capable of detecting and interpreting the nuances of each other's speech, posture, facial expressions, and so forth,' he says. 'These are essential to taking a medical history, forming a diagnosis, and making and communicating a treatment plan.'
What does that mean for the medical students hoping for careers in healthcare tomorrow? 'You had better have strong people skills,' says Dranove. 'If all you can bring to your patients is book learning — knowing what tests to order and what protocols to implement based on objective data — without the ability to make subjective decisions based on differences you perceive from one patient to another, then you might as well give way to the computer.'
Remember the term 'patient care,' he advises. 'If you are not good at the 'care,' then you may find yourself replaceable.'
It might also be useful to look at what is currently happening in nursing, with nurses unions already rising to the defense against AI encroachment in traditional nursing roles and new data already showing that AI could be far cheaper than human nurses ($9 per hour vs $35-$40 per hour for humans).
It makes sense to look at the future through the lens of basic business: If a new tech can lower costs, especially human ones, why would those cuts not be made? If a new tech can automate, streamline, and perform equally or better than a slower (human) method, why would that replacement not take place? If head-to-head doctor vs AI studies are happening now and AI is already winning, what will that competition look like in 25 years?
Still, D'Adderio isn't convinced that an AI-inspired people-purge is coming. 'Human judgement remains fundamentally important,' she says. She suspects that in another few decades, people will turn to AI tools as a first resource for their medical inquiries, 'much as they already do with Google.' And AI will probably be able to retrieve multimodal data and use it to improve its predictions. But D'Adderio finds it 'difficult to see AI entirely replacing clinicians, if not for the simplest tasks.'
Who (or What) Do You Trust?
In a recent Medscape interview, tech executive Peter Diamandis told the story of a close friend and colleague who felt ill and had seen several doctors over a period of months. No conclusive diagnosis was made until finally one doctor correctly diagnosed him with lymphoma.
When he got this news, his friend 'took his data from 3 months earlier and fed it into Claude 3.7 for a differential diagnosis,' says Diamandis. 'And lymphoma was number one on the list. From 3 months earlier. So I tell people, grab your data [and] get…not a second opinion — get an AI opinion. [T]hat's going to become more and more common.'
That crystalizes the current debate about AI today and what AI could one day become: Do you trust your doctor? Or do you trust a machine to get it right?
Big AI trust issues remain, especially with algorithms trained on online text, which could span everything from data taken from the Centers for Disease Control and Prevention and a thread shared on X.
'Ensuring factual accuracy and mitigating misinformation are critical research priorities for medical AI,' says Schaekermann, who claims AMIE only focuses on authoritative knowledge sources, such as curated medical datasets, clinical practice guidelines, and drug formularies, 'rather than learning uncontrollably from the open internet.'
But it's not just about the misinformation creeping into AI algorithms. Before they can be deployed in hospitals and used on patients, AI vendors need to undergo stringent quality and performance validation. But once approved, 'AI algorithms are 'frozen,' meaning that they cannot be allowed to change, or to learn from the data they process,' says D'Adderio.
What's more, AI algorithms are tested based on databases 'which may or may not represent the patient population in the hospital where they are adopted,' says D'Adderio. 'For example, the software might have been tested against an east European sample population and be used in a UK hospital. This means algorithms are inherently biased and need to be retested every time they are implemented at a new hospital site to verify their performance against the hospital's actual patient population.'
A 2024 Harvard study of GPT-3's diagnostic and triage ability found that AI could make the correct diagnosis 88% of the time, compared with 96% among human physicians (when given the same prompts). But the tool's accuracy was dependent on patient descriptions of their symptoms. Explanations that were poorly worded or lacked critical information — something a human doctor would be more likely to make sense of — caused AI to make more mistakes.
There's also the question of whether patients will want to share medical information with a chatbot rather than a flesh-and-blood person. A 2023 Pew survey found that 60% of Americans 'would feel uncomfortable if their own health care provider relied on artificial intelligence to do things like diagnose disease and recommend treatments.'
That same year, the mental health app Koko experimented with GPT-3 to compose encouraging messages for their 4000 users. But according to Koko cofounder Rob Morris, who shared his thoughts on X, although the tech did allow them to interact more quickly and efficiently, users weren't impressed.
The 'simulated empathy feels weird, empty,' Morris wrote. 'Machines don't have lived, human experience, so when they say 'that sounds hard' or 'I understand,' it sounds inauthentic.'
Humans and AI, Better Together
Some researchers warn that replacing physicians with AI runs the risk of 'Turing trap thinking,' says Nigam Shah, MBBS, PhD, professor of medicine at Stanford University and chief data scientist for Stanford Health Care. The Turing test, first proposed by computer scientist Alan Turing in 1950, suggested that if a machine can provide an answer that makes it indistinguishable from a human, then and only then can it be described as 'intelligent.'
Nigam Shah, MBBS, PhD
In 2023, Shah and his colleagues took a closer look at this theory in a medical setting, studying whether 430 volunteers could tell the difference between ChatGPT and a flesh-and-blood doctor. On average, patients correctly identified both the real doctor and their AI equivalent just 65% of the time. And they were less likely to trust a chatbot's diagnosis for high-risk or complex questions.
Rather than trying to outperform or replace humans, Shah says, the focus should be on how AI can complement human work. 'Today's thinking seems to imagine the human as either an overwatch — to catch AI's error — or an impediment to full value of AI,' he says. 'We need to ask the question: What are optimal human-AI teaming set-ups? Maybe AI does the screening to reduce human labor.'
The ideal integration of AI into medical diagnostics might involve finding how these two very unique kinds of expertise — the machine's ability to rapidly detect emergent patterns drawing on vast amounts of data, and human clinical judgement — can work together seamlessly. Even in another 25 years, 'humans will remain fundamental for complex diagnoses,' D'Adderio says. 'AI is not infallible; we still require clinicians to retrospectively verify the accuracy of its determinations.'
Mahmood's recent research on AI models for pathology, such as UNI and CONCH, has demonstrated how the technology can enhance diagnostic accuracy by leveraging large-scale datasets. His hope is that this will eventually allow for 'a more holistic and scalable approach to rare disease diagnosis,' he says.
But Schaekermann points out that even as AI becomes more sophisticated, with deeper reasoning and multimodality, 'we envision the technology primarily enhancing, not replacing, clinicians,' he says. 'Especially for complex interactions like checkups that rely heavily on human judgment, empathy, and the provider-patient relationship. The goal is for AI to handle specific tasks, freeing clinicians to focus on the human aspects of care.'
Shah recommends that any medical student hoping for a lasting career should do more than just familiarize themselves with data science and mathematics. It needs to become an academic priority. 'Many high school students are already developing good data sense,' he says. 'Which will position them very well to operate in the technology-heavy medical world of the future.'
Jesse Ehrenfeld, MD, former president of the American Medical Association, puts it more succinctly: ' AI is not going to replace doctors,' he says, 'but doctors using AI will replace doctors who aren't using AI.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Billionaire Bill Ackman Just Joined Warren Buffett and Cathie Wood by Adding This Monster Artificial Intelligence (AI) Stock to His Portfolio
Billionaire Bill Ackman Just Joined Warren Buffett and Cathie Wood by Adding This Monster Artificial Intelligence (AI) Stock to His Portfolio

Yahoo

timean hour ago

  • Yahoo

Billionaire Bill Ackman Just Joined Warren Buffett and Cathie Wood by Adding This Monster Artificial Intelligence (AI) Stock to His Portfolio

Buffett and Wood do not share the same investment philosophies, but both have Amazon in their portfolios. Ackman recently followed them, buying it on the dip in April. Ackman's position in Amazon complements his existing exposure to Alphabet. 10 stocks we like better than Amazon › Bill Ackman is a billionaire hedge fund manager as CEO of Pershing Square Capital Management. Unlike many of his peers on Wall Street, Ackman primarily keeps a tightly concentrated portfolio, with Pershing Square owning only about 10 stocks at any given time. For the last couple of years, Pershing Square's most direct artificial intelligence (AI) investment has been a sizable position in Alphabet. Ackman has made it clear that its diversified ecosystem -- spanning internet search, cloud computing, advertising, cybersecurity, and more -- combined with an attractive valuation is what enticed Pershing Square to take a position in the "Magnificent Seven" member. Well, just a few weeks ago, news broke that Pershing Square had recently initiated a position in another AI stock, Amazon (NASDAQ: AMZN). Ackman now joins Warren Buffett, whom he is known to admire, and Cathie Wood as prominent personalities on Wall Street who have exposure to Amazon, through their respective portfolios at Berkshire Hathaway and ARK Invest. Let's explore what makes Amazon such a compelling AI stock for the long haul. I'll break down some trends in the business and the company's valuation to help explain why Amazon has earned the approval of Ackman, Buffett, and Wood. Given how hot AI has become, investors may be challenged to identify which opportunities are best suited for long-term positions. What I mean by that is while semiconductor stocks or AI software businesses have risen in popularity over the last couple of years, it's hard to know which of these companies will continue to be a market leader in 10 years (or longer). To me, Amazon is like the business version of a Swiss Army knife. The company's core segments are e-commerce and cloud computing infrastructure via Amazon Web Services (AWS). But it also has a thriving advertising business and a growing subscription service (Amazon Prime), and it has even made some progress in the streaming and entertainment landscape. Similar to Alphabet, Amazon is uniquely positioned to stitch its various operating units together through more AI-powered services. In essence, by leveraging the power of AI, it can bolster both the consumer and enterprise sides of its business and make the platform increasingly sticky for its customers. While the ideas above sound great in theory, let's explore how the business has performed over the last couple of years since it started investing aggressively in AI. The first headline-grabbing move it made in AI was its investment in OpenAI rival Anthropic. The thesis around this partnership was to train Anthropic's generative AI model on AWS -- essentially integrating the efficiency of large language models into the AWS platform. Anthropic also agreed to use Amazon's in-house Trainium and Inferentia chipsets, providing the company with a direct avenue to begin scaling up a new part of its existing hardware business. Since Anthropic joined forces with Amazon, AWS revenue has accelerated considerably. But more important, operating income from Amazon's cloud business has almost doubled! When you consider that Amazon's AI-driven growth is primarily sourced through just the cloud business right now, it becomes clearer that the company can leverage its robust profitability to reinvest in other areas of its business and jump-start those, too. I think that comes into focus as Wall Street's consensus revenue and earnings estimates over the next few years suggest there is much more growth ahead. Like many of its peers in the technology sector, Amazon has enjoyed a bit of a roller coaster ride so far this year. Shares bottomed at roughly $167 in April, which is likely when Ackman pounced. I say that because Pershing Square's position in Amazon was not included in the company's form 13F filing for the first quarter (ended March 31). If you had bought the dip in Amazon when Ackman did, you would have paid around 27 times forward earnings. Among the 70 analysts who cover the stock, 66 rate it as either a buy or strong buy. Furthermore, with an average price target of $239, Wall Street's estimates imply there is still some modest upside. While Amazon's valuation has expanded over the last month and a half, the company's long-run prospects and added AI-centric uses still make it a reasonable buy in my view. Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet and Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, and Berkshire Hathaway. The Motley Fool has a disclosure policy. Billionaire Bill Ackman Just Joined Warren Buffett and Cathie Wood by Adding This Monster Artificial Intelligence (AI) Stock to His Portfolio was originally published by The Motley Fool

Time For Medicare Advantage Leaders—Including Me—To Eat Our Own Cooking
Time For Medicare Advantage Leaders—Including Me—To Eat Our Own Cooking

Forbes

timean hour ago

  • Forbes

Time For Medicare Advantage Leaders—Including Me—To Eat Our Own Cooking

Dr. Oz just turned 65 and became a Medicare beneficiary. Everyone who operates a Medicare plan ... More should be required to be one as well. In every industry, the best leaders live the experience of the customer. Car executives drive their own vehicles. Airline leaders occasionally fly coach. Restauranteurs eat from their own kitchen. But in healthcare—and specifically in Medicare Advantage (MA), which now serves more than 30 million Americans—the leaders designing these plans rarely, if ever, use them themselves. This disconnect breeds an empathy gap between decision-makers and the seniors whose lives and well-being depend on these products. It's time to close that gap. As Dr. Mehmet Oz turns 65 and qualifies for Medicare, he is in a unique position to lead the charge in fixing this blind spot. But I'm not letting myself off the hook either. As a current CEO of company that sells Medicare Advantage plans, I am proposing a standard that would apply to me and every other leader in this space: if you run a Medicare Advantage plan—or sit on its executive team that runs these plans—you should be required to enroll in that plan. No carve-outs. No executive-only exemptions. No platinum side-door coverage. For those of us under 65, the proposal would also require a structural change: expanding Medicare eligibility to allow MA plan executives early, voluntary enrollment in their own plans. We should not be allowed to claim ignorance or detachment simply because of our age. I want to be clear: if such an early-enrollment window existed, I would enroll myself. I should have to live under the same benefit design, customer service, and network constraints as every other member. Leaders like me—and my peers across the industry—must eat our own cooking.A Modest But Necessary Reform The proposal is simple but powerful: 1. All managed care CEOs and executive teams must enroll in their own MA plan. 2. Congress and CMS should create a new category of Medicare eligibility that allows executives under 65 to voluntarily enroll in their own MA plans in a 'test user' capacity. This is the only way for leadership to truly understand the member experience. 3. No waivers, no special coverage allowances. The goal is to force leadership to live the true plan reality: the prior authorizations, the formularies, the network restrictions, the call centers, the appeals It Matters—for Me, and for the Industry I don't make this proposal lightly—because it would apply to me, too. If this became law or industry standard tomorrow, I would sign up. And I believe most honest leaders would welcome the clarity and accountability it would bring. Here's why it matters:- Operational Truth: You only truly understand the friction points—customer service delays, billing errors, prescription denials—if you live them yourself.- Accountability: Plan leaders would no longer tolerate broken systems they themselves have to endure.- Culture Change: A company where the C-suite shares the same risks and frustrations as members cannot help but become more consumer-focused.- Public Trust: Medicare Advantage is under increasing scrutiny from policymakers and the public. This move would send a clear, ethical signal: we stand behind what we sell.- Policy Innovation: The best ideas for simplifying prior authorization, improving networks, and reducing out-of-pocket costs would come not from distant consultants—but from firsthand More 'Not For Me' Products Too much of healthcare is designed by people who never have to use it. Too many decisions are made in corporate conference rooms far removed from the lived experience of real patients. If Medicare Advantage is the future of healthcare for seniors—as so many believe—its architects must also live that future. That includes Dr. Oz. That includes every MA CEO. And that includes me. It's time for all of us to eat our own cooking.

Trump's Bill Would End EV Subsidies: Is Rivian in Trouble?
Trump's Bill Would End EV Subsidies: Is Rivian in Trouble?

Yahoo

timean hour ago

  • Yahoo

Trump's Bill Would End EV Subsidies: Is Rivian in Trouble?

Rivian is prepared to grow sales significantly regardless of tax incentives. But eliminating tax incentives could have an odd effect on Rivian's competitiveness. 10 stocks we like better than Rivian Automotive › Rivian Automotive (NASDAQ: RIVN) has a very promising future. Starting in early 2026, management expects to start production of three new affordable electric vehicles (EVs). Making affordable EVs priced under $50,000 is a huge milestone for an automaker. When Tesla released its affordable Model Y and Model 3 vehicles, sales boomed. Today, those two vehicles account for more than 90% of Tesla's auto sales. Some recent news, however, could be a giant blow to Rivian's growth plans. President Donald Trump's new bill proposes cutting federal EV tax credits, which would make electric vehicles $4,000 to $7,500 more expensive to buyers. How much will Rivian suffer? The answer might surprise you. Many investors are looking over electric car stocks to find the next Tesla. It's a worthy mission. Tesla shares have risen 23,000% in value since 2010. What's the key to spotting the next Tesla? Look for companies that can launch affordable models priced under $50,000. As mentioned, reaching this milestone creates a gigantic growth catalyst, making the automakers' models affordable to tens of millions of new buyers. Right now, Rivian is right on track. After releasing two luxury models with premium price tags -- very similar to what Tesla achieved with its Model S and Model X vehicles -- Rivian is preparing to start production of three new affordable models: the R2, R3, and R3X. Production is slated to begin in early 2026, but I'm not expecting full production of all three models until 2027 or 2028. Still, there's no doubt that Rivian is prepared to hit its biggest growth milestone in years. With $4.7 billion in cash on the books, plus a deal with Volkswagen that could deliver several more billion dollars in capital, Rivian looks like it has the means to get these vehicles to market. That will allow sales to surge, and also provide significantly more operational leverage, likely improving profit margins. Regardless of whether the EV tax credits are eliminated, Rivian has the capital to reach this growth catalyst, meaning sales growth should be expected whatever the future brings. Right now, Rivian's vehicles are priced between $70,000 and $100,000 depending on the exact package. If the company can price three new vehicles under the $50,000 mark, that makes its lineup significantly more affordable even without a tax incentive. In fact, eliminating the EV tax credit could end up helping Rivian long-term. It should be stressed that Trump's bill to eliminate EV tax credits is only a bill right now. It has a long way yet to becoming law. But if these eliminations are put into place, expect EV demand to drop over the near term. EVs are already struggling to maintain cost competitiveness versus gas or diesel engines. Adding $4,000 to $7,500 to the final cost should eliminate many potential buyers, especially those seeking long-term cost savings. Rivian also generates "free" income by selling automotive regulatory credits -- a major factor in the company achieving positive gross margins in recent quarters. Like Tesla, however, most of these credits are earned by state programs like California's, making them unlikely to be cut anytime soon. The important thing to note here is that most North American automakers don't yet have an affordable electric vehicle on the market, though most are trying. Consider Lucid Group, which aims to release several new mass market vehicles over the coming years. The company has less than $2 billion in cash on the balance sheet, and will almost certainly need more capital to get these cars to market. If its existing luxury models become even more expensive, that could lower demand and access to capital, making it harder for the company to actually get its affordable models to market. It's very possible the company could face severe financial uncertainty should these tax incentives be eliminated. Rivian, meanwhile, is already profitable on a gross margin basis, unlike Lucid, though it does partially rely on federal automotive regulatory credits to achieve this.. It's also much further along in the development of its affordable models than Lucid, making it much more likely it actually gets these models to market. If other competitors struggle financially due to lower EV tax incentives, it's possible Rivian could gain long-term. However, it should be noted that over the short term, Rivian should take a direct demand hit. The result is a mixed bag for Rivian. Demand would fall near-term due to higher costs for consumers. But a lessening of competition and investment by peers like Lucid Group could open up more long-term market share. Before you buy stock in Rivian Automotive, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rivian Automotive wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool recommends Volkswagen Ag. The Motley Fool has a disclosure policy. Trump's Bill Would End EV Subsidies: Is Rivian in Trouble? was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store